Evidence map›Paper›PMID 36268143›Full record

SynthesisComputational intelligence and neuroscience2022

C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.

Yingying Yang, Xiu Li, Hui Qian, Guangci Di, Ruhua Zhou, Yuwei Dong, Wenyue Chen, Qingling Ren

RetractedAbstract readMeta-AnalysisRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Computational intelligence and neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yingying YangDepartment of Gynaecology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.
Xiu LiDepartment of Gynaecology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.
Hui QianDepartment of Gastroenterology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.
Guangci DiDepartment of Gynaecology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.
Ruhua ZhouNursing Institute of Nanjing Medical University, No. 818, Tianyuan Street, Nanjing 210029, Jiangsu, China.
Yuwei DongDepartment of Gastroenterology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.
Wenyue ChenDepartment of Gynaecology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.
Qingling RenDepartment of Gynaecology, Affliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China.ORCID https://orcid.org/0000-0002-7383-9873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prognostic role of CRP (C-reactive protein) in gynecological tumors has been previously reported in individual studies, but whether CRP can be used as a separate potential prognostic factor has not been systematically reviewed. The purpose of this research is to determine if there is a link between CRP levels and the prognosis of gynecological cancer patients. Methods: A systematic search was carried out to find the literature evaluating the predictive role of CRP in the prognosis of gynecological cancer patients. For the purpose of determining the relationship between CRP and clinicopathological characteristics, the pooled odds ratio (OR) was calculated. A hazard ratio (HR) with a 95% confidence interval (CI) was used to determine differences in overall survival (OS), disease-free survival (DFS), or progression-free survival (PFS) between patients with low and high CRP levels. Results: A total of 19 studies, including 4062 patients, were analyzed retrospectively. The FIGO stage was related to the CRP level (OR = 0.43, 95% CI: 0.19-1.00). Age, lymph node metastasis, and histological grade were not associated with CRP level (OR = 0.93, 95% CI: 0.69-1.25; OR = 0.91, 95% CI: 0.65-1.28; OR = 0.74, 95% CI: 0.52-1.05). Worse OS (HR = 1.40, 95% CI: 1.23-1.57), DFS (HR = 1.20, 95% CI: 1.12-1.28), and PFS (HR = 1.57, 95%CI: 1.23-1.91) were associated with elevated CRP levels, as shown by the pooled results. Subgroup analysis was performed according to cancer type (endometrial cancer: HR = 1.15, 95% CI: 1.02-1.28; ovarian cancer: HR = 1.67, 95% CI: 1.03-2.31; cervical cancer: HR = 1.42, 95% CI: 1.19-1.64), multivariate value (HR = 1.22, 95% CI: 1.10-1.33), and age (HR = 1.50, 95% CI: 1.28-1.72). Significant correlations were observed between CRP and OS. Conclusions: CRP may be utilized as a prognostic indicator for a variety of gynecologic malignancies, including cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer.

Indexed as

C-Reactive ProteinGenital Neoplasms, FemaleBiomarkersFemaleHumansPrognosisRetrospective StudiesBiomarkersC-Reactive Protein

Identifiers

PMID36268143
PMCPMC9578838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.